# BeiGene

积极开发原创肿瘤生物制剂并将其商业化，面向国内和国际市场。

Source: https://cn.bioecon.ru/companies/beigene/
Updated: 2026-06-24

- 国家: China
- 代码: BGNE

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 成立 | 2010年 (2010) | https://www.businesswire.com/news/home/20210407005897/en/BeiGene-Announces-First-Commercial-Manufacturing-Approval-for-Its-State-of-the-Art-Biologics-Facility-in-Guangzhou-China, https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/R9.htm |
| 员工人数 | 全球11,000余名员工 (2024-12-31) | https://ir.beonemedicines.com/news/beigene-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-updates/ae4b526f-e135-4ce7-84fe-e9a8ba557406, https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/R9.htm |
| 营收 | 2024全年$38.1亿美元 (2024-12-31) | https://ir-api.eqs.com/media/document/6d80cd79-1b6f-4b3f-a71e-f4c6b04211ff/assets/BGNE-Earnings_Presentation_Q4_FY_2024_final.pdf?disposition=inline, https://last10k.com/sec-filings/onc/0001651308-25-000031.htm |
| 生产基地 | 中国广州（39英亩场地）；中国苏州（12.4英亩场地）；美国新泽西州Hopewell（42英亩场地） (2024-11-01) | https://beonemedicines.com/about/manufacturing/, https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf |
| 产能 | 广州：生物制品65,000升（可扩至200,000升）、口服固体制剂6亿；苏州：片剂3亿与胶囊3亿、生物制品1千升；Hopewell：生物制品8,000升（可扩至16,000升） (2024-11-01) | https://beonemedicines.com/about/manufacturing/, https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf |
| 认证 | GMP标准（美国FDA、EMA、TGA、中国NMPA、ANVISA等） (2024-11-01) | https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf |
| 监管批准 | 30余项批准与检查，涵盖美国FDA、EMA及中国NMPA；药品已在70多个市场获批 (2024-12-31) | https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf, https://ir.beonemedicines.com/news/beigene-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-updates/ae4b526f-e135-4ce7-84fe-e9a8ba557406, https://www.businesswire.com/news/home/20210407005897/en/BeiGene-Announces-First-Commercial-Manufacturing-Approval-for-Its-State-of-the-Art-Biologics-Facility-in-Guangzhou-China |

独立来源: beonemedicines.com, businesswire.com, ir-api.eqs.com, ir.beonemedicines.com, last10k.com, sec.gov

## 技术

- [PROTAC（靶向蛋白降解）](https://cn.bioecon.ru/technology/protacs/)
- [双特异性与多特异性抗体](https://cn.bioecon.ru/technology/bispecific-antibodies/)
- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)